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Abstract  
To observe the influence of adoptive immunotherapy combination with percutaneous microwave ablation (PMWA) on 
peripheral blood examination, hepatic function examination and serum alpha fetoprotein (AFP) in recurrent hepatocellular 
carcinoma (HCC) patients with hepatitis B. Fourteen recurrent HCC patients with 31 lesions (D≤6.0cm, fewer than four 
tumors) were treated with radical PMWA and continuous four courses of adoptive immunotherapy, which were administrated 
at 1, 2, 3 and 4 months after PMWA, respectively. Under sonographic guidance, tumor lysate-pulsed DCs (1ml) were injected 
into bilateral groin lymph nodes at 9th day, while CTL (25ml) were injected into the abdominal cavity at 11th day and CIK 
(100ml) was infused intravenously at 14th day after hemospasis in one course of treatment, respectively. Peripheral blood 
examination, serum AFP and hepatic function were reviewed 1, 3, 6 months after adoptive immunotherapy. The number of 
white blood cell (WBC), lymphocyte (LYM), serum albumin (ALB) and cholinesterase (CHE) were detected increase 
significantly at 3 and 6 months after therapy compared to pre-therapy (p<0.05). Platelet (PLT) was detected increased 
significantly at 6 months after therapy (p<0.05) compared to pre-therapy. Alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) were detected decreased significantly at 1, 3 and 6 months after therapy (p<0.05). As to serum AFP, it 
was detected decreased gradually, while there was no difference during the follow-up (6-16 months). No severe adverse 
effects were observed. Adoptive immunotherapy prescribed soon after PMWA was safe and ameliorated the laboratory 
examination and the immunity status of recurrent HCC patients, which may improve the prognosis. 
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Introduction 
Hepatocellular carcinoma (HCC) is one of the 
most aggressive and prevalent malignant 
diseases worldwide and characterized by a 
dismal prognosis. The incidence and mortality 
of HCC are increasing yearly. Most of the 
burden (85%) is borne in developing countries, 
with the highest incidence rates reported in 
regions where infection with hepatitis B virus 
(HBV) is endemic: Southeast Asia and 
sub-Saharan Africa [1-3]. Although current 
therapeutic modalities including liver 
transplantation, surgical resection, 
radiofrequency ablation (RFA), microwave 
ablation (MWA), percutaneous ethanol 
injection (PEI) and transcatheter hepatic 
arterial chemoembolization (TACE) have 
significantly improved in the last few decades 
and shown survival benefits for HCC patients, 
the survival rate is still unsatisfactory [4]. The 
main reason is the high recurrence rate after 
treatment [5, 6]. And the HCC patients are 
notoriously resistant to chemotherapy and 
radiotherapy [7]. So far, efficient therapeutic 
strategy to recurrent HCC patients is needed to 
be solved urgently. Meanwhile, recurrent HCC 
patients demonstrate some disordered in their 
blood subsets and hepatic function examination. 
This makes the antitumor effect reduced greatly. 
And a poor physical condition of recurrent 
HCC patients cannot afford invasive treatment. 
And medication-assisted therapies itself 
increase the burden on liver and damage the 
hepatic function further. This may contributes 
to the high recurrence rate after therapy. So 
searching therapeutic strategy both to improve 
the antitumor effect of recurrent HCC patients 
and to ameliorate the laboratory examination is 
imperative. 
Liver is an immunity organ itself [7], 
immunotherapy is an alternative promising 
treatment strategy for many cancer types 
including HCC. It aims to provide or enhance 
innate or adoptive immunity against 
malignancies by harnessing the immune system 
to target tumors [9]. Several lines of evidence 
indicated that immunotherapy was often a 
synergistic partner for efficacy in combinations 
therapy without additive toxicity [10, 11]. 
Advances in the immunotherapy of cancer have 
also been met with a number of setbacks and 
achieved preliminary clinical efficacy in 
primary HCC [8, 12]. The adoptive 
immunotherapy focuses on adoptive immune 
system (T and B cells), including cytotoxic T 
lymphocytes (CTL), cytokine-induced killer 
cells (CIK), dendritic cells (DCs), 
tumor-infiltrating T lymphocytes (TIL) and so 
on [13]. The activation of tumor-specific CTL 
requires three synergistic signals: the 
presentation of tumor antigen by 
antigen-presenting cells (APC) to specific 
T-helper cells, the interaction between 
costimulatory factors and the secretion of 
immunostimulatory cytokines from activated 
T-helper cells [14]. DCs are potent professional 
APCs that can capture, process and present 
antigens. They are critical for exerting 
T-cell-mediated immune responses, activating 
naïve T cells and playing a critical role in 
innate immune response and adoptive immune 
response [15]. CIK cells are shown to be a 
heterogeneous population of which majority 
expresses both the T-cell marker CD3 and 
natural killer cell marker CD56. CTL and CIK 
cells are effective antigen-specific and 
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-nonspecific tumor-killing effectors. Adoptive 
immunotherapy with mature autologous DCs 
pulsed with tumor lysate ex vivo or 
antigen-specific and -nonspecific antitumor 
effectors have been demonstrated with variable 
efficacy. Adoptive immunotherapy with DCs, 
CTL and CIK has been demonstrated with 
obvious clinical effect [16, 17]. 
Percutaneous microwave ablation (PMWA) 
as a thermal ablation method not only reduces 
tumor load, but also can remove 
immunosuppression from tumor by enhancing 
release and exposure of tumor-related antigens 
from the death and apoptosis tumor cells, which 
further might help to overcome the immune 
tolerance towards the tumor. PMWA has 
achieved a satisfactory clinical efficacy in 
primary and recurrent HCC patients [18, 19]. 
Therefore, such immune-stimulating 
therapeutic interventions in combination with 
immunotherapy strategy represent a promising 
future approach for HCC treatment [13, 20]. 
This preliminary study was a combination 
therapy of PMWA and adoptive immunotherapy 
for recurrent HCC patients, which applied 
multiple immunocytes infusion including 
mature DCs, CTL and CIK. The aim was to 
observe it`s safety and influence on peripheral 
blood routine, serum alpha-fetoprotein (AFP) 
and hepatic function examination in recurrent 
HCC patients with hepatitis B. 
Material and method 
Patients 
From August 2011 to November 2012, 14 
patients (10 male, 4 female) with recurrent 
HCC aged 40 - 80 years (mean 59.8 ± 11.9 
years) were treated with PMWA by the 
guidance of sonography or contrast-enhanced 
sonography (CEUS) and continuous four 
courses of adoptive immunotherapy, which 
were administrated 1, 2, 3 and 4 months after 
PMWA. The study was approved by the local 
research ethics committee of Chinese PLA 
General Hospital. Written informed consent 
was obtained from all patients before their 
enrollment into the study. Inclusion criteria 
included the followings: 1) the diameter of 
single nodular ≤ 6cm and the number of 
nodular ≤ 4; 2) absence of portal vein 
thrombosis or extrahepatic metastases; 3) 
Child-Pugh classification A or B; 4) without 
clinically significant ischemic heart disease or 
cardiac failure; 5) tumor accessible via a 
percutaneous approach; 6) cirrhosis with 
chronic hepatitis B; 7) expected survival of 
more than six months; 8) be able to comply 
with the immunotherapy program strictly. 
Laboratory examinations necessary for 
inclusion were as follows: WBC ≥ 2 x 109/L; 
PLT ≥ 75 x 109/L; the proportion of PLM ≥ 
20%. Exclusion criteria: 1) the expectation 
survival of the recurrent HCC patients is less 
than 3 months; 2) the patients who is not able to 
comply with treatment. The characteristics of 
14 recurrent HCC patients recruited into the 
study were listed in Table 1. Before receiving 
combination therapy, 8 patients received liver 
surgical resection, 4 patients PMWA or PRFA 
and 2 patients TACE. Although all patients in 
the study were HBV related, the HBV viral 
burden examination was lower than 500 
(copies/ml). For inducing the hepatotoxicity of 
antiviral drug, all patients were not received 
antiviral therapy for HBV.
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Table 1 Clinical data of fourteen recurrent HCC a patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Recurrent time: the recurrent time after the first-treatment 
 
Num Gen Age HBV history  
(years) 
Num  
of nodules 
Max diameter 
 (mm) 
differentiation First-treament *Recurrent time 
(months) 
Child-plug 
1 M 46 20 1 15 well Surgical resection and TACE 5 5 
2 M 74 32 3 35 moderate PWMA 38 5 
3 M 60 24 1 38 moderate Surgical resection and TACE 4 4 
4 F 61 17 1 12 poor PRFA 8 6 
5 M 54 26 3 30 well Surgical resection and TACE 13 5 
6 M 52 21 2 20 moderate Surgical resection 21 5 
7 F 69 39 1 41 moderate laparoscope RFA 22 6 
8 F 71 27 3 29 moderate TACE 3 7 
9 F 47 19 4 28 moderate Surgical resection 25 4 
10 M 70 23 2 52 well PWMA 11 5 
11 M 51 22 1 58 moderate Surgical resection 61 5 
12 M 80 41 2 24 moderate TACE 1 6 
13 F 40 13 3 29 poor PWMA 9 5 
14 M 62 33 4 35 moderate Surgical resection and TACE 12 5 
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Microwave ablation equipment and 
techniques 
Two patients with 4 nodules, 4 patients with 3 
nodules, 3 patients with 2 nodules and 5 
patients with single nodule received PMWA 
successfully. All patients were recruited as 
inpatients. The treatments were performed at 
the authors’ institution and were implemented 
by the guidance of sonographic or CEUS. 
General anesthesia was achieved by using a 
combination of two anesthetics (propofo and 
ketamine). Two types of microwave equipment, 
KY-2000 and KY-2100 microwave applicators 
(Kangyou Medical, Nanjing, China) with a 
frequency of 2450 MHz and 915 MHz 
separately, were used in the study [21, 22]. The 
applicators can deliver a maximum power of 
100 W through one or two 15-gauge internally 
cooled antennae, and are equipped with a 
thermal monitoring system connected to three 
21-gauge tissue thermal monitoring needles.  
Ablation treatment was designed and 
performed to ablate tumors completely with a 
single treatment session. A detailed protocol 
was worked out for each patient based on the 
size and position of the tumor, characteristics 
of the thermal field distribution of microwave 
antenna, and the authors’ clinical ablation 
experience of 20 years [23]. In general, for 
tumors < 1.7 cm in diameter, a single antenna 
was used; for tumors ≥1.7 cm, multiple 
antennae were applied synchronously or 
consecutively. An output setting of 60 W for 
300 seconds was routinely used. With 
sonographic guidance, one to three 21-gauge 
tissue thermal monitoring needles were placed 
at different sites 0.5 cm outside the tumor to 
monitor temperature throughout the procedure. 
The treatment session was ended if the 
hyperechoic region observed by sonography 
covered the entire tumor, or if the monitored 
temperature reached 60°C, or remained at 54°C 
for at least 3 minutes. Otherwise, an increase in 
application time was required depending on the 
temperature which was monitored dynamically 
[23, 24].  
Immunotherapy protocol 
Four continuous courses of adoptive 
immunotherapy were performed from 1 to 4 
months after PMWA, and which course lasts 14 
days listed in Fig. 1. Tumor tissue was obtained 
by sonography-guided biopsy using an 
18-gauge needle before PMWA for pathologic 
diagnosis and lysate preparation. Before every 
course, patients were checked review imaging 
and blood examination without new lesion or 
recurrence, and then the hemospasia were 
carried out. Immunocytes were separated and 
differentiated from peripheral blood 
mononuclear cells (PBMCs) in 50 ml peripheral 
blood. Under sonographic guidance, mature 
DCs (mDC) cells (1-2×10
8
) which cultured 
mature on 9th days in 1 ml physiologic saline 
was injected into bilateral groin lymph nodes 
(0.5 ml for each), CTL (DC-CIK) cells (20ml, 
1-5×10
9
) were injected into right upper 
abdominal cavity after 11th days (Fig. 2) and 
CIK cells (100ml, 1-5×10
9
) were infused 
intravenously after 14th days after haemospasia, 
respectively.
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Figure 1 The combination therapy of PMWA and adoptive immunotherapy protocol. This figure shows that 
the flow chart of PWMA and continuous four courses adoptive immunotherapy subsequently. 
 
 
Figure 2 Immunocytes injected into the bilateral groin lymph nodes (A, white arrow: lymph nodes; yellow 
arrow: 21G PTC-B needle) and right upper abdominal cavity (B, white arrow: cavity; yellow arrow: cell 
persusion) 
 
Preparation of DCs and effector cells 
from peripheral blood 
Immunocytes were prepared according to the 
method of Romani in a Good Manufacturing 
Practice (GMP)-compliant facility [25]. 
PBMCs were collected via density gradient 
centrifugation over Ficol-Paque, and were 
suspended in 10ml STEM-34 and lay aside for 
3 hours to adhere onto a plastic surface. After 
non-adherent cells were removed, the adherent 
cells were cultured at 37°C in STEM-34 
supplemented with 1,000U/mL 
granulocyte-monocyte colony-stimulating 
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factor and 500U/mL IL-4. Fifty percent of DC 
medium was changed every other day and the 
medium was supplemented which cytokines. 
Immature DCs were harvested on day 9 for 
injection and pulsed with antogenic tumor 
lysate before undergoing a maturation step in 
culture medium containing tumor necrosis 
factor α. To generate CIK cells, non-adherent 
cells were cultured at 37°C in KBM-551 
serum-free medium supplemented with 
1,000U/mL interferon γ on the initial day. After 
24 hours of incubation, 2ug/ml mAb CD3, 
1ug/ml CD28 mAb, and 500u/mL IL-2 were 
added. Fresh IL-2 and fresh media were 
replenished every other day. CIK cells were 
harvested on day 14 for injection. 
Pathological diagnosis, clinical 
observations and follow-up 
Histological diagnosis was obtained by biopsy 
in all patients. Laboratory examinations, 
sonography, CEUS, contrast-enhanced CT 
and/or MRI were performed before and 1, 3, 
6months and every 6 months subsequently after 
the combination therapy. Laboratory 
examinations included peripheral routine blood 
examination, serum AFP and hepatic function. 
Statistical analysis   
The statistical analysis was performed using 
SPSS version 16.0 (Chicago, IL, USA). 
Continuous data were expressed as means ± 
standard deviations (SD) and median. For 
comparison between multiple groups, analysis 
of variance or rank sum test were carried out as 
appropriate. For comparison between two 
groups, independent-samples t-test, rank sum 
test and Chi-square test were carried out. 
Two-tailed p < 0.05 was judged to be 
significant. 
Results 
Toxicity assessment  
No serious adverse events occurred in a total of 
168 times of cell infusions (three times of cell 
infusions in one course). A total of 26 adverse 
events were recorded. Adverse events included 
grade I/II fever defining as ≤ 38.5°C (21 times, 
32.8%) that could be recovered without deal 
with in 6-24h, and malaise (5 times, 7.8%) that 
could be recovered without deal with in 2–24 
hours. There were no significant hepatic, renal, 
pulmonary, cardiac, hematological or 
neurological toxicities attributable to the cell 
infusions. No clinical manifestation of 
autoimmune reaction was observed.  
Changes in routine blood 
examination  
As shown in Table 2, the number of WBC, 
LYM and PLT of peripheral routine blood 
examination was detected increased 
significantly. As to WBC, there was 
significantly increased at 3 and 6 months 
post-therapy compared with pre-therapy 
examination (p<0.05). For LYM, compared 
with that of pre-therapy, 3 and 6 months 
post-therapy examination results showed 
obviously increased (p<0.05). Compared with 
pre-therapy PLT examination, 3 months 
post-therapy examination results showed a 
increased trend and it showed significantly 
statistical difference at 6 months (p<0.001). 
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Table 2 Phenotype of peripheral blood examination analysis before and 1, 3, 6 months after combination therapy 
      Phenotype 
 Time points 
WBC (10
9
/L) LYM (10
9
/L) PLT (10
9
/L) 
Pre-therapy 4.23±0.74 1.37±0.53 118.79±44.47 
Post-therapy    
1 month 4.56±1.18 1.60±0.49 124.50±50.31 
3 months 5.06±1.22* 1.85±0.67* 129.79±54.16 
6 months 5.18±1.22* 2.12±1.01* 166.64±51.73** 
*Significantly difference was detected, p < 0.05 
** Significantly difference was detected, p < 0.001 
 
 
Changes in hepatic function 
examination 
As shown in Table 3, compared with 
pre-therapy hepatic function examination, the 
post-therapy examination has improved greatly. 
For ALT, the examination of 1, 3, 6 months 
post-therapy have decreased sharply with a 
significantly difference (p<0.05) compared with 
that of pre-therapy. As to AST, the examination 
of 1, 3, 6 months post-therapy have decreased 
radically with a significant difference compared 
with that of pre-therapy (p<0.05). To ALP, it 
was detected an sharply decreasing trend till to 
6 months post-therapy with significant 
difference (p<0.001) compared with 
pre-therapy. For serum albumin (ALB), the 3 
and 6 months post-therapy examination have 
increased sharply with a significant difference 
compared with that of pre-therapy (p<0.001). 
To CHE, the examinations of 3 and 6 months 
post-therapy have increased sharply with a 
significant difference compared with that of 
pre-therapy (p<0.05). As to TBIL and DBIL, 
the 1, 3 and 6 months post-therapy examination 
results showed a decreased trend compared 
with that of pre-therapy, but with no significant 
difference. 
Changes in alpha fetoprotein (AFP) 
Compared with pre-therapy AFP examination 
(146.87 ± 229.16μg/L), the examination of 1, 3, 
6 months post-therapy were 181.57 ± 
329.47μg/L, 102.72 ± 167.94μg/L and 75.95 ± 
142.07μg/L, respectively. Although there was a 
sharply decreased trend, the significant 
statistical difference was not detected (Table 3). 
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Table 3 Hepatic function analysis before and 1, 3, 6 months after combination therapy 
Phenotype 
Time points 
ALT(U/L) AST(U/L) ALP(U/L) ALB( g/L) CHE(U/L) TBiL(μmol/L) DBiL(μmol/L) 
Pre-therapy 56.25±60.24 62.77±88.17 89.51±29.96 38.99±4.17 5036±1914 17.41±9.69 6.62±4.08 
Post-therapy        
1 month 45.14±49.90* 37.17±36.71* 96.77±27.82 39.61±5.68 5465±1685 18.25±8.57 6.60±3.67 
3 months 30.42±16.70* 28.29±9.66* 84.39±23.37 43.10±5.16* 6125±1430* 16.15±8.08 6.26±3.36 
6 months 18.80±14.02* 22.70±11.11* 55.31±20.29** 47.50±8.89* 6856±1669* 14.80±10.43 6.04±3.91 
*Significantly difference was detected, p < 0.05 
** Significantly difference was detected, p < 0.001 
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Discussion 
As to recurrent HCC patients, the treatment was 
limited. Most patients have lost the opportunity 
of re-operation. While, PWMA as a safe, 
feasible and efficient minimally invasive 
method was widely used in clinical, and 
achieved gratifying results [18]. Recurrent 
HCC patients also face a higher risk of 
recurrence after re-treatment. How to prevent 
relapse in HCC has become the “bottleneck” of 
improving the prognosis. With the development 
of tumor immunology, a large number of basic 
and clinical researches confirmed that 
postoperative recurrence of HCC patients was 
correlated with their immune status. And 
adoptive immunotherapy could decrease 
postoperative recurrence and improve 
recurrence-free outcomes for HCC [26, 27]. For 
most of the recurrence of postoperative HCC 
occurs during the 6 months after operation. 
Adoptive immunotherapy can eliminate these 
residual cancer cells and destroy the 
proliferating cancer cells [12, 28]. Timely 
postoperative immunotherapy is necessary. So 
in this study, we investigate the feasible, safety 
and efficient of combination therapy with 
PWMA and adoptive immunotherapy in 
recurrent HCC patients. 
The results of this study shown 
adoptive immunity could improve the number 
of WBC, LYM and PLT of peripheral routine 
blood examination greatly in recurrent HCC 
patients. It is reported that the number of WBC 
and LYM in peripheral were positive correlated 
to the immunity status [13]. As has reported, 
immunotherapy can improve the number and 
the phenotypes of lymphocyte which indicate 
the immunity status and the prognosis of cancer 
patients directly [29].  
The number of PLT is related to 
hematopoietic system and splenic function in 
HCC patients. The majority of recurrence HCC 
patients were companied with esophageal 
gastric varices and hypersplenism, and lower 
PLT increases the risk of bleeding. 
Immunotherapy can increase the number of 
platelets and reduce the risk of bleeding, which 
benefits to the mortality of HCC patients.  
PMWA can reduce the tumor burden and 
increase release of the tumor-associated antigen 
which further promotes the efficacy of 
immunotherapy. The synergy effect of 
immunotherapy and PWMA of liver tumor 
improve hepatic function significantly. This 
study showed ALT, AST, ALP, TBIL and DBIL 
have greatly decreased post-therapy. Among of 
the indexes, ALT, AST and ALP of have 
significant statistic difference compared to the 
examination of pre-therapy. Bilirubin is a major 
metabolite iron porphyrin compounds, which is 
toxic to brain and nervous system and can cause 
irreversible damage. Bilirubin is an important 
index for diagnosis of clinically jaundice and 
reflects hepatic function. And bilirubin is the 
main product of the spleen engulfing red blood 
cells, which reduced indicates the improvement 
splenic function and anemia. So the 
improvement in hepatic function may benefit to 
the life quality and prognosis of recurrent HCC 
patients. Because the serum CHE is synthesized 
by the liver, therefore decreased enzyme 
activity often reflects hepatic function damage. 
Meanwhile serum ALB is an indicator of liver 
protein synthesis function. So in this study, the 
serum CHE and ALB were increased obviously 
which reflected the promotion of hepatic 
function in recurrent HCC patients.  
In this study, although the serum 
alpha-fetoprotein measurement of recurrence 
HCC patients post-therapy showed no 
significantly statistical difference comparing 
with pre-therapy, there was an obviously 
downward trend. Meanwhile, the relationship 
of serum alpha-fetoprotein measurement with 
the prognosis of HCC patients was reported yet 
[30]. 
Since HCC recurrence is just one of the 
causes of death in HCC patients, the other 
causes of death including hepatic function 
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failure, poor immunity status and infection, 
gastrointestinal bleeding and hepatic 
encephalopathy [31]. Therefore, by improving 
the patients' immune status and liver function 
can be achieved for improving the survival 
period of recurrent HCC patients. As a matter 
of fact, adoptive immunotherapy ameliorated 
some of the symptoms including increasing 
appetite, improving sleep, gaining body weight, 
and relieving pain [32]. Hence, immunotherapy 
may also improve the quality of life of 
postoperative patients. 
However, this study was a preliminary one. 
The sample size was small, more significant 
changes may be seen by enlarging sample size. 
The follow-up period was rather short and the 
indexes that we used for evaluation need to be 
optimized. Longer follow-up period may show 
the benefits on the combination therapy of 
PWMA and adoptive immunotherapy to the 
prognosis of recurrent HCC patients. 
In conclusion, this trial demonstrated that 
combination therapy of adoptive 
immunotherapy prescribed soon after PMWA 
for recurrence HCC patients was safe and 
ameliorated peripheral routine blood, hepatic 
function examination and serum 
alpha-fetoprotein measurement. Meanwhile 
these changes may improve the prognosis of 
recurrent HCC patients. The clinical effect 
should be further confirmed by a randomized 
controlled clinical trial with a larger sample 
size and a longer follow-up period. 
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